Evidence map›Paper›PMID 31662796›Full record

ArticleTherapeutic advances in medical oncology2019

The effect of CELLFOOD

Barbara Nuvoli, Bruno Amadio, Giancarlo Cortese, Serena Benedetti, Barbara Antoniani, Antonella Soriani, Mariantonia Carosi, Lidia Strigari, Rossella Galati

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Application of Cyclodextrin for Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Barbara NuvoliPreclinical Models and New Therapeutic Agent Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Bruno AmadioSAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Giancarlo CorteseSAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Serena BenedettiDepartment of Biomolecular Sciences, University of Urbino 'Carlo Bo', Urbino, Italy.
Barbara AntonianiAnatomy Pathology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Antonella SorianiLaboratory of Medical Physics and Expert Systems, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Mariantonia CarosiAnatomy Pathology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Lidia StrigariLaboratory of Medical Physics and Expert Systems, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Rossella GalatiPreclinical Models and New Therapeutic Agent Unit, IRCCS Regina Elena National Cancer Institute, Via Chianesi, Rome 00144, Italy.ORCID https://orcid.org/0000-0003-2646-8384
Istituti di Ricovero e Cura a Carattere Scientifico · ITExpert System (Italy) · ITUniversity of Urbino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBased on previous observations that the nutraceutical CELLFOOD™ (CF), the 'physiological modulator' that aimed to make oxygen available 'on demand', inhibits the growth of cancer cells, this study was designed to investigate the role of CF in the regulation of hypoxia-inducible factor 1 alpha (HIF1α) and its correlated proteins, phosphoglycerate kinase 1 and vascular endothelial growth factor. Our idea was that CF, acting on HIF1α, in combination with current anticancer therapies could improve their effectiveness.

methodsTo evaluate the effect of CF in association with radiotherapy and chemotherapy, different human cancer cell lines and mice with mesothelioma were analysed by tumour growth, clonogenic assay, western blot and immunohistochemical analysis.

resultsCF in combination with radiation with or without cisplatin increases the death rate of cancer cells.

conclusionsCollectively, results from preclinical trials suggest that CF could be a useful intervention to improve the efficacy of radiotherapy or combined treatment strategies and could be a promising treatment modality to counteract cancer.

Indexed as

CELLFOODTMcombined treatment strategiesHIF1αmesotheliomaradiosensitivity

Identifiers

PMID31662796
PMCPMC6792276
OpenAlexW2979451499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.